

# ARE NOVEL PSYCHOACTIVE SUBSTANCES (NPS) THAT SHARE STRUCTURAL MOTIFS WITH APPROVED COMPOUNDS MORE LIKELY TO HAVE A PSYCHOACTIVE EFFECT?

Michael Chary, MD, PhD

Department of Emergency Medicine, Weill Cornell College of Medicine



Weill Cornell  
Medicine

## INTRODUCTION

- Novel Psychoactive Substances (NPS) emerge too quickly to characterize them one-by-one in the laboratory.
- NPS are extensively discussed in online forums, providing an untapped source of data on natural experimentation.
- NPS are extensively chemically modified from their original scaffolds.
- It is difficult to separate fact from fiction online.


## CONCEPTUAL FRAMEWORK

Reports of effects of online substances are more credible if the substances share structural features with approved therapeutics.

## RESEARCH QUESTION

What structural similarities are there between NPS and approved therapeutics?

## METHODS



**Morgan Fingerprint** All fragments of a molecule up to 4 molecules in length

**Tanimoto Similarity** Fraction of Morgan fingerprints that two molecules share

**Hierarchical Clustering** Group substances together based on their Tanimoto similarities. Substances within a group have higher similarity to each other than to any substance not in the group.

## ACKNOWLEDGMENTS

We thank the Department of Emergency Medicine at Weill Cornell and the NIH Division of Loan Repayment.

## RESULTS




Figure 2: **Structural Similarity of Novel Psychoactive Substances & Approved Compounds.** X- and y-axes show names of substances. Only every 3<sup>rd</sup> name shown for sake of space. Darkness of each square in represents the structural similarity of the compounds indicated by the x- and y-axes. Colorbar in upper left shows scale for structural similarity. Row and column dendograms indicate groups of structurally similar compounds.




Figure 3: **Type of Substances in Each Cluster.** X-axis shows cluster number. Y-axis shows the fraction of substances in each cluster that are FDA-approved.

Cluster	Example Substances
1	FDA Sodium nitrite, gallium-67 citrate, talc, sodium thiosulfate, magnesium carbonate NPS 1,4-butanediol
2	FDA acamprosate calcium, acetazolamide, acetic acid, acetohydroxamic acid, acetrizoate sodium, alprostadil, misoprostol, iotrolan NPS 1,3-dimethylbutylamine, 2-methyl-2-butanol, 2-methyl-2-pentanol, 3-aminoisobutyric acid BOB, MET, methylhexanamine, oxiracetam, piracetam, pramiracetam
3	FDA oxymorphone, estramustine, dextromethorphan, paricalcitol, ulipristal, fluorometholone NPS DOC, Tetrahydrogestrinone, metribolone, dimethyltrienolone, trestolone, prostanazol, methasterone, clostebol, HU-308, metenolone enanthate
4	FDA abaloparotide, histrelin, bilvarudin, gonadorelin, goserelin NPS BPC-157, GHRP-2, examorelin, tesamorelin, melanotan
5	FDA abacavir, entrectinib, aripiprazole, phenelzine, mitotane, bumetanide, cefmetazole, iofexidine NPS 1P-ETH-LAD, 4-chlorobutylcathinone, MDA-19, isoproscaline, 4-fluoromethcathinone, 5-methoxymethylene, PTI-2, AB-PICA, desoxyprasadrol, meprylcaine, 5F-AMB

Table 1: Example members of each cluster. FDA, substances approved by the United States Food & Drug Administration. NPS, novel psychoactive substances. LAD, lysergic acid diethylamide, BOB, beta-methoxy-2C-B, MET, methyltryptamine, DOC, 2,5-dimethoxy-4-chloroamphetamine, MDA-19, synthetic CB<sub>1</sub> agonist

## CONCLUSIONS

- Computational methods can identify similarities between the two-dimensional structures of novel psychoactive substances and substances approved by the FDA for medical use. Cluster 5 contained the most FDA-approved psychoactive substances and the most NPS.
- Computational methods can identify structural similarities between NPS and drugs that are not psychoactive, providing a way to predict additional effects that arise from side chain modification.

## LIMITATIONS

- Our conclusions are limited by the approximation of chemicals achiral structures with no distinguishing 3D features or resonance structures.
- We did not assess the fraction of NPS compounds in clusters with FDA-approved compounds that were known not to be psychoactive in the amounts usually consumed. Nor did we compare the performance of our algorithm to other approaches.